Fifth Chinese COVID-19 vaccine enters phase-3 clinical trials

Share on WhatsApp

Beijing: Chinese vaccine maker Anhui Zhifei Longcom Biopharmaceutical Co., Ltd. has commenced the phase-3 clinical trials for its Covid-19 vaccine, planning to recruit 29,000 volunteers across the world.

This is China’s first phase-3 efficacy study for a recombinant subunit COVID-19 vaccine candidate, the company said in a statement Thursday.…

This news comes via ChinaPulse.com, which delivers news, data, analysis, and insights on Chinese business, travel, finance, health, military, investment, and technology.

Visit the original:
ChinaPulse.com

Comments are closed.